N-propyl-5-(1,2-dithiolan-3-yl)pentanamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二硫杂环戊烷
• 英文名称: N-propyl-5-(1,2-dithiolan-3-yl)pentanamide
• 英文别名: 5-(1,2-dithiolan-3-yl)-N-propylvaleramide；5-(dithiolan-3-yl)-N-propylpentanamide
• 化学式: C₁₁H₂₁NOS₂
• 分子量: 247.426
• InChiKey: NZIVQUUUIHFGAI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  15
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.91
• 拓扑面积：
  79.7
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  正丙胺 、 Thioctic acid 在 immobilized Candida antarctica Lipase B 作用下， 以 1,4-二氧六环 为溶剂， 反应 72.0h， 以68%的产率得到N-propyl-5-(1,2-dithiolan-3-yl)pentanamide
  参考文献：
  名称：

  脂肪酶催化的羧酸和胺的酰胺化

  摘要：

  酰胺化反应是非常特别感兴趣的，特别是在制药工业中，并且总是需要用大量过量的反应物来活化酸。因此，产生大量废物。为了减少这种反应对环境的影响，我们开发了酶促酰胺化条件，该条件可与多种胺和酸，特别是与生物相关的硫辛酸兼容。水是该反应过程中产生的唯一副产物，因此获得了很高的原子经济性。另外，我们已经表明脂肪酶可以被回收并重复使用几次而没有明显的活性损失。

  DOI：

  10.1016/j.tetlet.2018.04.049

文献信息

• Lipase-catalyzed amidation of carboxylic acid and amines
  作者：Daniela Manova、Florian Gallier、Lotfi Tak-Tak、Lyubov Yotava、Nadège Lubin-Germain

  DOI：10.1016/j.tetlet.2018.04.049

  日期：2018.5

  The amidation reaction is of a very particular interest, especially in the pharmaceutical industry and always requires the activation of the acid with a large excess of reactants. Therefore, a large amount of waste is generated. In order to reduce the environmental impact of such reaction, we have developed enzymatic amidation conditions which are compatible with a wide range of amines and acids, in

  酰胺化反应是非常特别感兴趣的，特别是在制药工业中，并且总是需要用大量过量的反应物来活化酸。因此，产生大量废物。为了减少这种反应对环境的影响，我们开发了酶促酰胺化条件，该条件可与多种胺和酸，特别是与生物相关的硫辛酸兼容。水是该反应过程中产生的唯一副产物，因此获得了很高的原子经济性。另外，我们已经表明脂肪酶可以被回收并重复使用几次而没有明显的活性损失。
• CONTROLLING THE ARCHITECTURE, COORDINATION, AND REACTIVITY OF NANOPARTICLE COATING UTILIZING AN AMINO ACID CENTRAL SCAFFOLD
  申请人：The Florida State University Research Foundation, Inc.

  公开号：US20170168042A1

  公开（公告）日：2017-06-15

  A series of multicoordinating and multifunctional ligands optimized for the surface-functionalization of luminescent quantum dots (QDs) and gold nanoparticles (AuNPs) alike is disclosed. An L-aspartic acid precursor is modified with functionality, through simple peptide coupling chemistry, one or two lipoic acid (LA) groups and poly(ethylene glycol) (PEG) moieties in the same ligand. These ligands were combined with a new photoligation strategy to yield hydrophilic and reactive QDs that are colloidally stable over a broad range of conditions, including storage at nanomolar concentration and under ambient conditions.

  本文介绍了一系列经过优化的多配位和多功能配体，可用于表面功能化发光量子点（QDs）和金纳米颗粒（AuNPs）。通过简单的肽偶联化学，将L-天冬氨酸前体修饰为具有功能性的配体，其中包含一到两个硫辛酸（LA）基团和聚乙二醇（PEG）基团。将这些配体与新的光化学连接策略相结合，可以产生亲水性和反应性的QDs，在广泛的条件下具有胶体稳定性，包括在纳摩尔浓度和常温下储存。
• ALPHA-LIPOIC ACID DERIVATIVES AND THEIR USE IN DRUG PREPARATION
  申请人：Brufani Mario

  公开号：US20110212954A1

  公开（公告）日：2011-09-01

  The present invention concerns an enantiomer R of a compound of Formula (I), wherein X is —NH—R 1 or of Formula (V) or (VI), R 1 is —(CH 2 ) n —R 2 , R 2 is a linear, branched or cyclic C 1 C 6 aliphatic group, —O—(CH 2 ) n —CH 3 , —NH—CO—(CH 2 ) n —CH 3 , a 5- or 6-membered aliphatic or aromatic ring optionally comprising a heteroatom, a 5- or 6-membered aromatic ring substituted by one or two substituents, said substituents being selected from the group consisting of —OH, —O(alkyl C 1 C 3 ) and —OCO(alkyl C 1 C 3 ), or of Formula (V), R 3 is H or a C 1 -C 3 aliphatic group and R 4 is a linear C 1 -C 3 or a branched C 3 -C 12 aliphatic group, or R 3 is a C 1 -C 3 aliphatic group and R 4 is a linear C 1 -C 12 aliphatic group, Y is O, CH—(CH 2 ) n —CH 3 or N(CO)(CH 2 ) n —CH 3 , and n is an integer from O to 6. It has been found that the enantiomers of the invention are able to release (R)-alpha-lipoic acid, ensuring a longer permanence in the body for the pharmacologically active principle than that obtainable by its direct administration, or to simulate the pharmacological action of alpha-lipoic acid itself, while exhibiting a much more intense and lasting activity.
• Lipoyl Compounds And Their Use for Treating Ischemic Injury
  申请人：Baguisi Alexander B.

  公开号：US20130237483A1

  公开（公告）日：2013-09-12

  The present invention relates, in various embodiments, to a compound represented by Structural Formula (I), pharmaceutically acceptable salts or prodrugs thereof, and compositions comprising said compounds, or pharmaceutically acceptable salts or prodrugs thereof. Methods of using compounds of Structural Formulas (I) and (la) or compositions comprising compounds of Structural Formulas (I) and (la), or pharmaceutically acceptable salts or prodrugs thereof, to treat ischemia or ischemia-reperfusion injury are also disclosed.
• LIPOYL COMPOUNDS AND METHODS FOR TREATING ISCHEMIC INJURY
  申请人：Ischemix LLC

  公开号：US20150065564A1

  公开（公告）日：2015-03-05

  The present invention relates, in various embodiments, to a compound represented by Structural Formula (I), pharmaceutically acceptable salts or prodrugs thereof, and compositions comprising said compounds, or pharmaceutically acceptable salts or prodrugs thereof. Methods of using compounds of Structural Formulas (I) and (Ia) or compositions comprising compounds of Structural Formulas (I) and (Ia), or pharmaceutically acceptable salts or prodrugs thereof, to treat ischemia or ischemia-reperfusion injury are also disclosed.